- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT05847179
Faza 2, otwarte badanie oceniające bezpieczeństwo i tolerancję progeryniny w zespole Wernera
Otwarte badanie fazy 2 oceniające bezpieczeństwo i tolerancję progeryniny w leczeniu utraty gęstości mineralnej kości (BMD) u pacjentów z typowym zespołem Wernera
This is a Phase 2, open-label study to A Phase 2, Open-Label Study to Evaluate the Safety and Tolerability of Progerinin for the Treatment of Bone Mineral Density (BMD) Loss in Subjects with Typical Werner Syndrome.
There will be up to 5 subjects that will receive treatment with Progerinin twice daily for approximately 1 year.
Przegląd badań
Szczegółowy opis
Subjects who have successfully completed the Screening phase will enter the baseline and treatment phase of the study. Subjects will take the assigned treatment of Progerinin (2400 mg) split as 1200 mg BID in the morning and evening with food for 1-Year.
To evaluate the safety and tolerability of Progerinin for the treatment of BMD loss in subjects with typical Werner syndrome.
The secondary objectives of this study are:
- To characterize the activity of Progerinin on bone metabolism in subjects with typical Werner Syndrome.
- To evaluate vascular function in subjects with typical Werner Syndrome.
- To evaluate glucose metabolism and insulin resistance in subjects with typical Werner Syndrome.
- To evaluate lipid metabolism in subjects with typical Werner Syndrome.
- To evaluate physical function in subjects with typical Werner Syndrome.
- To evaluate the pharmacokinetics (PK) of Progerinin sachet administered twice daily (BID) in subjects with typical Werner Syndrome.
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 2
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Christine Lee
- Numer telefonu: 301-540-2600
- E-mail: christinelee@kcrnresearch.com
Lokalizacje studiów
-
-
Michigan
-
Ann Arbor, Michigan, Stany Zjednoczone, 48109
- Rekrutacyjny
- University of Michigan
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
[Inclusion Criteria]
-
Subjects must be at least ≥ 18 years of age.
-
Subjects should have a confirmed diagnosis of typical Werner syndrome by genetic analysis.
-
Subjects should be osteopenic (T-score between -1.0 and -2.5) or have confirmed osteoporosis (T-score ≤ -2.5) at screening/baseline. Subjects may continue to receive bone supplements (e.g., bisphosphonates, calcium supplements, Vitamin D supplements, etc.) as appropriate per standard of care throughout the study.
-
Male or non-pregnant, non-lactating female.
-
Subjects screening blood chemistry inclusive of metabolic panel, hematology, and urine analysis results should be acceptable to the investigator.
-
Negative pregnancy test for female subjects as described below. Women of child bearing potential (WOCBP) and Women not of child-bearing potential are eligible to participate. Both women of childbearing potential and women of non-child-bearing potential should use an approved method of birth control and agrees to continue to use this method for the duration of the study and for 90 days after last treatment.
Acceptable methods of contraception include abstinence, female subject/partner's use of hormonal contraceptive (oral, implanted, or injected) in conjunction with a barrier method (WOCBP only), female subject/partner's use of an intrauterine device (IUD), or if the female subject/partner is surgically sterile or two years post-menopausal. All male subjects/partners must agree to use a In addition, subjects may not donate sperm for the duration of the study and for 90 days after last treatment.
Females who are less than two (2) years post-menopausal, those with tubal ligations and those using contraception must have a negative serum pregnancy test at baseline within the one (1) week prior to the first study medication administration. Every six weeks, and at study termination a pregnancy test should be performed, either serum or urine stick test. However, if the urine result is positive, a serum pregnancy test will be performed.
-
Provide signed written informed consent and willingness, ability to comply with study requirements.
-
Subject must have a projected life expectancy of ≥ 12 months in the opinion of the Investigator.
[Exclusion Criteria]
-
Subject with clinical signs seen at screening are at the final stage of Werner syndrome progression, and completion of the study is difficult to be assessed, including:
- Subjects who received continuous or intermittent home oxygen therapy for 6 months before obtaining consent
- Subjects who received at least 2 hospitalizations for pneumonia during the 12 months prior to obtaining consent
- Subjects who have at least 10% net weight loss and have not recovered. This includes significant net weight loss over the last six months.
-
Subjects with significant dehydration as judged by the principal investigator.
-
Subjects with pericardial fluid, ascites and pleural effusion.
-
Therapy with investigational drugs within 30 days of beginning study medication.
-
History of prior malignancy, except for adequately treated in situ cancer, basal cell, squamous cell skin cancer, or other cancers (e.g., breast, prostate) for which the subject has been disease-free for at least 3 years.
-
Any serious medical condition, laboratory abnormality, psychiatric illness, or comorbidity that, in the judgment of the Investigator, would make the subject inappropriate for the study.
-
Serious systemic fungal, bacterial, viral, or other infection that is not controlled or requires intravenous (IV) treatment for infection(s).
-
Subjects with known history of having Acquired Immunodeficiency Syndrome (AIDS) or with a history known to be infected with Human Immunodeficiency Virus (HIV).
-
Subjects with a history of serious drug hypersensitivity or allergic reaction such as anaphylaxis or any component of the formulation.
-
Clinically significant bleeding within 2 weeks prior to baseline (e.g., gastrointestinal [GI] bleeding, intracranial hemorrhage).
-
Medical or recreational use of marijuana or THC-containing compounds within 3 months of screening visit and for the duration of the trial.
-
Pregnant or lactating women.
-
Major surgery, defined as any surgical procedure that involves general anesthesia and a significant incision (i.e., larger than what is required for placement of central venous access, percutaneous feeding tube, or biopsy), within 28 days prior to baseline or anticipated surgery during the study period.
-
Inability to return for scheduled treatment and assessments.
-
Subjects that require concomitant use of any medications or substances that are strong inhibitors or inducers of CYP2D6 or CYP2C8
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Treatment Group
all subjects will receive Progerinin 2400mg (1200mg twice daily) after morning and evening meals for a year |
This is a Phase 2, open-label study to evaluate the safety and Tolerability of Progerinin for the treatment of BMD Bone Mineral Density (BMD) Loss in Subjects with Typical Werner Syndrome. . There will be up to 5 subjects that will receive treatment with Progerinin twice daily for approximately 1 year. This study will have three phases: Screening Phase, Treatment Phase, and Follow-Up Phase. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)
Ramy czasowe: Baseline to Week 56 (including 4-week follow-up)
|
The intensity of the event will be graded using CTCAE v6.0 criteria |
Baseline to Week 56 (including 4-week follow-up)
|
|
Incidence of Treatment-Related Adverse Events
Ramy czasowe: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Incidence of Serious Adverse Events (SAEs)
Ramy czasowe: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Incidence of TEAEs and SAEs leading to discontinuation of study medication
Ramy czasowe: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Blood Chemistry from Baseline
Ramy czasowe: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Hematology from Baseline
Ramy czasowe: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Urinalysis Results from Baseline
Ramy czasowe: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Height (cm) from Baseline
Ramy czasowe: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Weight (kg) from baseline
Ramy czasowe: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Temperature (°C) from baseline
Ramy czasowe: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Pulse Rate (beats per minute) from baseline
Ramy czasowe: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Respiratory Rate (breaths per minute) from baseline
Ramy czasowe: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Systolic Blood pressure (mmHg) from baseline
Ramy czasowe: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Diastolic Blood pressure (mmHg) from baseline
Ramy czasowe: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Physical Examination findings from baseline
Ramy czasowe: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Change in ECG Ventricular Rate (beats per minute) from baseline
Ramy czasowe: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Change in ECG PR interval (msec) from baseline
Ramy czasowe: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Change in ECG QRS interval (msec) from baseline
Ramy czasowe: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Change in ECG QT interval (msec) from baseline
Ramy czasowe: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Change in ECG QTc interval (msec) from baseline
Ramy czasowe: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
Miary wyników drugorzędnych
Miara wyniku |
Ramy czasowe |
|---|---|
|
Change in Femur Bone Mineral Density (BMD) from baseline
Ramy czasowe: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Lumbar Spine BMD from baseline
Ramy czasowe: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Aortic Pulse Wave Velocity (m/s) from baseline
Ramy czasowe: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Insulin Resistance by Oral Glucose Tolerance Test (OGTT) from baseline
Ramy czasowe: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Lipid Profile from baseline
Ramy czasowe: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Handgrip Strength Test from baseline
Ramy czasowe: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Short Physical Performance Battery (SPPB) Total Score from baseline
Ramy czasowe: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Ankle-Brachial Pressure Index (ABPI) from baseline
Ramy czasowe: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Bone-Specific Alkaline Phosphatase (BAP) from baseline
Ramy czasowe: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Osteocalcin (OC) from baseline
Ramy czasowe: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Procollagen Peptides (P1NP) from baseline
Ramy czasowe: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Deoxypyridinium (DPD) from baseline
Ramy czasowe: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in C-Terminal Telopeptide of Type 1 Collagen (CTX) from baseline
Ramy czasowe: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Pharmacokinetic Parameters of Progerinin at the Specified PK Assessment Visits
Ramy czasowe: Baseline, Week12, Week 24, Week 36 and Week 52
|
Baseline, Week12, Week 24, Week 36 and Week 52
|
Współpracownicy i badacze
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- PRG-PRO-004
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .